Cargando…
Spotlight Commentary: How to prove pharmacology of immunomodulatory drugs in a phase 1 trial?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595300/ https://www.ncbi.nlm.nih.gov/pubmed/31020696 http://dx.doi.org/10.1111/bcp.13928 |
| _version_ | 1783430377210118144 |
|---|---|
| author | Rissmann, Robert Szabadi, Elemer |
| author_facet | Rissmann, Robert Szabadi, Elemer |
| author_sort | Rissmann, Robert |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6595300 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-65953002019-07-11 Spotlight Commentary: How to prove pharmacology of immunomodulatory drugs in a phase 1 trial? Rissmann, Robert Szabadi, Elemer Br J Clin Pharmacol Spotlight Commentaries John Wiley and Sons Inc. 2019-04-25 2019-07 /pmc/articles/PMC6595300/ /pubmed/31020696 http://dx.doi.org/10.1111/bcp.13928 Text en © 2019 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| spellingShingle | Spotlight Commentaries Rissmann, Robert Szabadi, Elemer Spotlight Commentary: How to prove pharmacology of immunomodulatory drugs in a phase 1 trial? |
| title | Spotlight Commentary: How to prove pharmacology of immunomodulatory drugs in a phase 1 trial? |
| title_full | Spotlight Commentary: How to prove pharmacology of immunomodulatory drugs in a phase 1 trial? |
| title_fullStr | Spotlight Commentary: How to prove pharmacology of immunomodulatory drugs in a phase 1 trial? |
| title_full_unstemmed | Spotlight Commentary: How to prove pharmacology of immunomodulatory drugs in a phase 1 trial? |
| title_short | Spotlight Commentary: How to prove pharmacology of immunomodulatory drugs in a phase 1 trial? |
| title_sort | spotlight commentary: how to prove pharmacology of immunomodulatory drugs in a phase 1 trial? |
| topic | Spotlight Commentaries |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595300/ https://www.ncbi.nlm.nih.gov/pubmed/31020696 http://dx.doi.org/10.1111/bcp.13928 |
| work_keys_str_mv | AT rissmannrobert spotlightcommentaryhowtoprovepharmacologyofimmunomodulatorydrugsinaphase1trial AT szabadielemer spotlightcommentaryhowtoprovepharmacologyofimmunomodulatorydrugsinaphase1trial |